| SpyGlass Pharma, Inc. |
10%+ Owner |
Common Stock |
6,035,038 |
$167,955,108 |
$27.83 |
09 Feb 2026 |
Direct |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
7,692,298 |
$146,153,662 |
$19.00 |
28 Jun 2021 |
Direct |
| MBX Biosciences, Inc. |
10%+ Owner |
Common Stock |
3,614,486 |
$38,638,855 |
$10.69 |
16 Sep 2024 |
Direct |
| Korro Bio, Inc. |
10%+ Owner |
Common Stock |
1,297,893 |
$14,419,591 |
$11.11 |
10 Mar 2026 |
Direct |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
$0 |
$6.84 |
02 Oct 2025 |
Direct |
| Korro Bio, Inc. |
10%+ Owner |
Pre-Funded Warrants |
242,945 |
|
|
10 Mar 2026 |
Direct |
| MBX Biosciences, Inc. |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
16 Sep 2024 |
Direct |
| MBX Biosciences, Inc. |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
16 Sep 2024 |
Direct |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series A-2 convertible preferred stock |
0 |
|
|
28 Jun 2021 |
Direct |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
28 Jun 2021 |
Direct |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series C convertible preferred Stock |
0 |
|
|
28 Jun 2021 |
Direct |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Series A Convertible Perpetual Preferred Stock |
0 |
|
|
02 Oct 2025 |
Direct |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Series B Convertible Perpetual Preferred Stock |
0 |
|
|
02 Oct 2025 |
Direct |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
02 Oct 2025 |
Direct |
| SpyGlass Pharma, Inc. |
10%+ Owner |
Series B Preferred Stock |
0 |
|
|
09 Feb 2026 |
Direct |
| SpyGlass Pharma, Inc. |
10%+ Owner |
Series C-1 Preferred Stock |
0 |
|
|
09 Feb 2026 |
Direct |
| SpyGlass Pharma, Inc. |
10%+ Owner |
Series C-2 Preferred Stock |
0 |
|
|
09 Feb 2026 |
Direct |
| SpyGlass Pharma, Inc. |
10%+ Owner |
Series D Preferred Stock |
0 |
|
|
09 Feb 2026 |
Direct |